ReviewClinical interventions in aging2017
Recent developments in age-related macular degeneration: a review.
Review in Clinical interventions in aging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 209 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
209 citing papers in PubMed, 6 syntheses or guidelines pooled it, 409 citations in OpenAlex.
- Risk factors for wet macular degeneration: a systematic review, with novel insights from the Scottish Heart Health Extended Cohort.BMC ophthalmology · 2025Pooled it
- Artificial intelligence for diagnosing exudative age-related macular degeneration.The Cochrane database of systematic reviews · 2024Pooled it
- The Hippo signalling pathway and its impact on eye diseases.Journal of cellular and molecular medicine · 2024Pooled it
- The role of the cytokine TNF-α in choroidal neovascularization: a systematic review.Eye (London, England) · 2024Pooled it
- Characteristics of choroidal neovascularization in elderly eyes with high myopia not meeting the pathologic myopia definition.Scientific reports · 2022Pooled it
- Periodontal Disease and Age-Related Macular Degeneration: A Meta-Analysis of 112,240 Participants.BioMed research international · 2020Pooled it
- Trial
- Mannose-modified miR-223 nanoparticles remodel pathological microenvironment to suppress inflammation and angiogenesis for neovascular AMD therapy.International journal of pharmaceutics: X · 2026Article
- Article
- Pre- and post-COVID-19 changes in retinal disease patterns in Türkiye: insights from a tertiary hospital.International ophthalmology · 2026Article
- Non neovascular Age - related macular degeneration - Review on clinical and imaging advances.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Review
- Assessing the Safety and Efficacy of Agonistic Monoclonal Antibody against Robo4 versus Ranibizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Phase I, Open-Label, Multicenter Study.Ophthalmology science · 2026Article
- Evaluation of primary care physicians' knowledge, attitudes, and awareness levels regarding age-related macular degeneration.BMC primary care · 2026Article
- The effect of age on wound healing in the laser induced choroidal neovascularization model.Experimental eye research · 2026Article
- Article
- Biomarker-Specific Test-Retest Repeatabilities of Microperimetry in Neovascular Age-Related Macular Degeneration.Ophthalmology science · 2026Article
- Visual Acuity and Intraretinal Fluid as Predictive Factors for Legal Blindness and Macular Atrophy in Neovascular AMD Eyes Treated with Anti-VEGF: A Swedish Real-World Study.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Beyond transcription: RNA-binding proteins steering angiogenesis.American journal of physiology. Heart and circulatory physiology · 2026Review
- Association between ABO and Rh blood groups and subtypes of age-related macular degeneration: A cross-sectional study.PloS one · 2026Article
- Formulation Development andCurrent drug delivery · 2026Article
149 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVisual impairment in elderly people is a considerable health problem that significantly affects quality of life of millions worldwide. The magnitude of this issue is becoming more evident with an aging population and an increasing number of older individuals.
objectiveThe objective of this article was to review the clinical and pathological aspects of age-related macular degeneration (AMD), diagnostic tools, and therapeutic modalities presently available or underway for both atrophic and wet forms of the disease.
methodsAn online review of the PubMed database was performed, searching for the key words. The search was limited to articles published since 1980 to date.
resultsSeveral risk factors have been linked to AMD, such as age (>60 years), lifestyle (smoking and diet), and family history. Although the pathogenesis of AMD remains unclear, genetic factors have been implicated in the condition. Treatment for atrophic AMD is mainly close observation, coupled with nutritional supplements such as zinc and antioxidants, whereas treatment of wet AMD is based on targeting choroidal neovascular membranes.
conclusionIdentification of modifiable risk factors would improve the possibilities of preventing the progression of AMD. The role of anti-vascular endothelial growth factor (anti-VEGF) agents has transformed the therapeutic approach of the potentially blinding disease "wet AMD" into a more favorable outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.